Further Insights into the Measurement of Free Polysaccharide in Meningococcal Conjugate Vaccines

被引:1
作者
Beresford, Nicola J. [1 ]
De Benedetto, Gianluigi [1 ]
Lockyer, Kay [1 ]
Gao, Fang [1 ]
Burkin, Karena [1 ]
Lalwani, Karan [1 ]
Bolgiano, Barbara [1 ]
机构
[1] Med & Healthcare Prod Regulatory Agcy, Sci Res & Innovat Div, South Mimms EN6 3QG, England
关键词
CRM; filtration; glycoconjugate; HPAEC; HPLC; meningitis; meningococcal; Neisseria meningitidis; stability; ANION-EXCHANGE CHROMATOGRAPHY; INFLUENZAE TYPE-B; ULTRAFILTRATION BEHAVIOR; PNEUMOCOCCAL POLYSACCHARIDES; CAPSULAR POLYSACCHARIDES; GLYCOCONJUGATE VACCINES; DIPHTHERIA-TOXIN; SACCHARIDE; STABILITY; SEROGROUP;
D O I
10.3390/vaccines13020167
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The purpose of this study was to further characterize the ultrafiltration (UF) method for determining free saccharide levels in glycoconjugate vaccines and compare it with other methods used for the determination of free saccharide levels in meningococcal glycoconjugate vaccines. Methods: We performed experiments on both meningococcal glycoconjugates and capsular polysaccharides, and compared UF, deoxycholate (DOC) precipitation, and solid-phase extraction (SPE) methods. Meningococcal capsular polysaccharides from groups A (MenA), C (MenC), and W (MenW) were depolymerized and characterized using SEC-MALS (size-exclusion chromatography with multi-angle laser light scattering) to determine the molecular weight and hydrodynamic size and then subjected to UF. The free saccharide content was quantified using HPAEC-PAD (high-performance anion-exchange chromatography with pulsed amperometric detection). Results: The characterization of size-reduced group C polysaccharide revealed weight-average molecular mass (Mw) ranging from 22,200 g/mol to 287,300 g/mol and hydrodynamic radii of 3.7 to 19.5 nm. Pore size studies confirmed that polysaccharides with diameters up to 15 nm filtered through the 100 kDa cellulose membrane. The smallest PS fragment tested (22,200 g/mol, 7.4 nm diameter) was partially recovered from the 30 kDa membrane. For MenC-CRM197, DOC yielded the lowest free saccharide content (<1%), UF gave moderate results (7-8%), and SPE showed the highest and most variable values (up to 15%). For MenA- and MenW-CRM197, UF and DOC consistently provided low free saccharide levels (<2% and 3-11%, respectively). Conclusions: The upper limits on the size of free group C meningococcal polysaccharides that can be ultrafiltered were assessed. Differences in the relative amount of free saccharide were observed between various methods used to control meningococcal conjugate vaccines.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
    Trotter, Caroline L.
    Maiden, Martin C. J.
    EXPERT REVIEW OF VACCINES, 2009, 8 (07) : 851 - 861
  • [22] Quantitation of novel pentavalent meningococcal polysaccharide conjugate vaccine (Men A-TT, Men C-CRM, Men Y-CRM, Men W-CRM, Men X-TT) using sandwich ELISA
    Phugare, Swapnil
    Kale, Sameer
    Sharma, Pankaj
    Goel, Sunil Kumar
    Gairola, Sunil
    Jadhav, Suresh S.
    VACCINE, 2020, 38 (49) : 7815 - 7824
  • [23] Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines
    Rohokale, Rajendra
    Guo, Zhongwu
    ACS INFECTIOUS DISEASES, 2023, 9 (02): : 178 - 212
  • [24] Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers
    Tregnaghi, Miguel
    Lopez, Pio
    Stamboulian, Daniel
    Grana, Gabriela
    Odrljin, Tatjana
    Bedell, Lisa
    Dull, Peter M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 26 : 22 - 30
  • [25] Process development and immunogenicity studies on a serogroup 'X' Meningococcal polysaccharide conjugate vaccine
    Chilukuri, Srinivas Reddy
    Reddy, Peddi
    Avalaskar, Nikhil
    Mallya, Asha
    Pisal, Sambhaji
    Dhere, Rajeev M.
    BIOLOGICALS, 2014, 42 (03) : 160 - 168
  • [26] Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines
    Jódar, L
    Griffiths, E
    Feavers, I
    VACCINE, 2004, 22 (08) : 1047 - 1053
  • [27] Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults
    de Voer, Richarda M.
    van der Klis, Fiona R. M.
    Engels, Carla W. A. M.
    Schepp, Rutger M.
    van de Kassteele, Jan
    Sanders, Elisabeth A. M.
    Rijkers, Ger T.
    Berbers, Guy A. M.
    VACCINE, 2009, 27 (50) : 6974 - 6982
  • [28] Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule
    Ladhani, Shamez N.
    Andrews, Nick J.
    Waight, Pauline
    Hallis, Bassam
    Matheson, Mary
    England, Anna
    Findlow, Helen
    Bai, Xilian
    Borrow, Ray
    Burbidge, Polly
    Pearce, Emma
    Goldblatt, David
    Miller, Elizabeth
    VACCINE, 2015, 33 (05) : 648 - 655
  • [29] Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A + C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial
    Choo, S
    Zuckerman, J
    Goilav, C
    Hatzmann, E
    Everard, J
    Finn, A
    VACCINE, 2000, 18 (24) : 2686 - 2692
  • [30] Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine
    Qiao, Weilin
    Ji, Shaoyang
    Zhao, Yubao
    Hu, Tao
    VACCINE, 2015, 33 (17) : 2066 - 2072